IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions

Area of Science:

• Dermatology
• Immunology
• Genetics

Background:

• Psoriasis is a common inflammatory skin disease with non-specific biomarkers.
• Existing biomarkers often lack specificity for psoriasis compared to other inflammatory skin disorders.

Purpose of the Study:

• To identify specific biomarkers for psoriasis using gene expression analysis.
• To evaluate the diagnostic and prognostic potential of identified biomarkers in psoriasis patients.

Main Methods:

• Unsupervised cluster analysis of gene expression profiles from 150 psoriasis patients and controls with other inflammatory skin diseases.
• Immunohistochemical analysis of IL-36γ expression in skin lesions.
• Correlation analysis of serum IL-36γ levels with disease activity and treatment response.

Main Results:

• A distinct cluster of IL-17/tumor necrosis factor-α (TNFα)-associated genes, including IL-36γ, was identified specifically in psoriasis.
• IL-36γ was exclusively expressed in psoriasis lesions and its serum levels correlated with disease activity.
• IL-36γ levels decreased after anti-TNFα treatment and aided in differentiating psoriasis from eczema.

Conclusions:

• IL-36γ is a highly specific and valuable biomarker for psoriasis diagnosis and monitoring disease activity.
• IL-36γ may serve as a potential therapeutic target due to its role in psoriatic inflammation pathways.
• IL-36γ aids in the differential diagnosis of inflammatory skin conditions.